personalized neoantigen vaccine
Showing 1 - 25 of >10,000
Pancreatic Tumor Trial in Shanghai (Personalized neoantigen vaccine)
Recruiting
- Pancreatic Tumor
- Personalized neoantigen vaccine
-
Shanghai, Shanghai, ChinaChanghai Hospital
Mar 8, 2022
Advanced Renal Cell Carcinoma Trial in Heilbronn (IVAC)
Recruiting
- Advanced Renal Cell Carcinoma
- IVAC
-
Heilbronn, GermanySLK Kliniken Heilbronn, Klinik für Innere Medizin III: Hämatolog
Nov 30, 2022
Solid Tumor Trial in Beijing (Personalized neoantigen tumor vaccine)
Not yet recruiting
- Solid Tumor
- Personalized neoantigen tumor vaccine
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Apr 28, 2022
Gastric Cancer, Esophageal Cancer, Liver Cancer Trial in Beijing (neoantigen tumor vaccine with or without PD-1/L1)
Recruiting
- Gastric Cancer
- +2 more
- neoantigen tumor vaccine with or without PD-1/L1
-
Beijing, Beijing, ChinaPLA General Hospital
Jan 27, 2022
Resectable Esophageal Cancer Trial in Hangzhou (iNeo-Vac-P01, GM-CSF)
Recruiting
- Resectable Esophageal Cancer
- iNeo-Vac-P01
- GM-CSF
-
Hangzhou, Zhejiang, ChinaThe Second Affiliated Hospital of Zhejiang University
Mar 23, 2022
Glioblastoma Trial in Boston (radiation, biological, drug)
Recruiting
- Glioblastoma
- Radiation Therapy
- +3 more
-
Boston, Massachusetts
- +1 more
May 31, 2022
Advanced Malignant Solid Tumors Trial in Nanchang (Neoantigen peptide vaccine, Neoantigen-based DC immune preparation)
Not yet recruiting
- Advanced Malignant Solid Tumors
- Neoantigen peptide vaccine
- Neoantigen-based DC immune preparation
-
Nanchang, Jiangxi, ChinaFirst Affiliated Hospital of Nanchang University
Mar 1, 2023
Resectable Pancreatic Cancer Trial in Hangzhou (iNeo-Vac-P01, GM-CSF)
Recruiting
- Resectable Pancreatic Cancer
- iNeo-Vac-P01
- GM-CSF
-
Hangzhou, Zhejiang, ChinaZhejiang Provincial People's Hospital
Nov 15, 2021
Unmethylated Glioblastoma Trial in Saint Louis (Personalized Neoantigen DNA vaccine, Retifanlimab, TDS-IM v 2.0 electroporation
Not yet recruiting
- Unmethylated Glioblastoma
- Personalized Neoantigen DNA vaccine
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Feb 14, 2023
Digestive System Tumors Trial in Hangzhou (iNeo-Vac-R01)
Recruiting
- Digestive System Neoplasms
- iNeo-Vac-R01
-
Hangzhou, Zhejiang, ChinaDepartment of General Surgery, Institute of Minimally Invasive S
Sep 8, 2023
Advanced Solid Tumor Trial in Shanghai (Personalized neoantigen tumor vaccine)
Recruiting
- Advanced Solid Tumor
- Personalized neoantigen tumor vaccine
-
Shanghai, Shanghai, ChinaRuijin Hospital Shanghai Jiaotong University School of Medicine
Jun 24, 2023
Advanced Pancreatic Cancer Trial in Qionghai (Personalized neoantigen tumor vaccine)
Recruiting
- Advanced Pancreatic Cancer
- Personalized neoantigen tumor vaccine
-
Qionghai, Hainan, ChinaRuijin-Hainan Hospital Affiliated to Shanghai Jiao Tong Universi
Jun 14, 2023
Gastric Cancer Trial in Beijing (neoantigen tumor vaccine with or without PD-1/L1)
Not yet recruiting
- Gastric Cancer
- neoantigen tumor vaccine with or without PD-1/L1
-
Beijing, ChinaDepartment of GI Oncology, Peking University Cancer Hospital,
Jan 26, 2022
Digestive System Tumors Trial in Hangzhou (iNeo-Vac-R01 in combination with standard adjuvant therapy)
Recruiting
- Digestive System Neoplasms
- iNeo-Vac-R01 in combination with standard adjuvant therapy
-
Hangzhou, Zhejiang, ChinaDepartment of General Surgery, Institute of Minimally Invasive S
Sep 8, 2023
Digestive System Tumors Trial in Hangzhou (iNeo-Vac-R01)
Recruiting
- Digestive System Neoplasms
- iNeo-Vac-R01
-
Hangzhou, Zhejiang, ChinaDepartment of General Surgery, Institute of Minimally Invasive S
Sep 8, 2023
HCC Trial in Baltimore, New York, Auckland (biological, drug, device)
Recruiting
- HCC
- GNOS-PV02
- +3 more
-
Baltimore, Maryland
- +2 more
Apr 26, 2022
Cancer, Solid Tumor Trial in San Francisco (Personalized Synthetic Long Peptide Vaccine)
Enrolling by invitation
- Cancer
- Solid Tumor
- Personalized Synthetic Long Peptide Vaccine
-
San Francisco, CaliforniaQuest Clinical Research
Feb 20, 2023
Urothelial/Bladder Cancer, Nos Trial in New York (Atezolizumab, PGV001, Poly ICLC)
Completed
- Urothelial/Bladder Cancer, Nos
- Atezolizumab
- +3 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Mar 7, 2022
Follicular Lymphoma Trial in Boston (Rituximab, Neo Vax, Pembrolizumab)
Recruiting
- Follicular Lymphoma
- Rituximab
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 14, 2022
Posto Perative Hepatocellular Carcinoma Trial (Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I
Not yet recruiting
- Posto Perative Hepatocellular Carcinoma
- Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection
- (no location specified)
Feb 27, 2023
Refractory Tumor, Solid Tumor Trial in Kaohsiung, Tainan (Dendritic Cell Vaccine, Lenvatinib, Nivolumab)
Not yet recruiting
- Refractory Tumor
- Solid Tumor
- Dendritic Cell Vaccine
- +2 more
-
Kaohsiung, Taiwan
- +2 more
Mar 2, 2023
Kidney Cancer Trial in Boston (NeoVax, Ipilimumab)
Recruiting
- Kidney Cancer
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 22, 2022
Carcinoma, Melanoma, Bladder Cancer Trial in Chengdu (Tumor antigen-sensitized DC vaccine and their sensitized T cells
Not yet recruiting
- Carcinoma
- +3 more
- Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration
-
Chengdu, Sichuan, ChinaWest China Hospital
Feb 10, 2022
Advanced Malignant Solid Tumor Trial in Hangzhou (iNeo-Vac-P01, GM-CSF)
Active, not recruiting
- Advanced Malignant Solid Tumor
- iNeo-Vac-P01
- GM-CSF
-
Hangzhou, Zhejiang, ChinaSir Run Run Shaw Hospital
Nov 15, 2021
Pancreatic Cancer, Pancreatic Carcinoma Trial in Hangzhou (iNeo-Vac-P01, GM-CSF)
Completed
- Pancreatic Cancer
- Pancreatic Carcinoma
- iNeo-Vac-P01
- GM-CSF
-
Hangzhou, Zhejiang, ChinaZhejiang Provincial People's Hospital
Nov 15, 2021